ライフサイエンスコーパス: drug metabolism

1 tably impairs phagocytosis, and increases TB drug metabolism.

2 potential to suppress PXR-regulated phase-I drug metabolism.

3 ese findings have important implications for drug metabolism.

4 ng lipid metabolism, cell proliferation, and drug metabolism.

5 (RFB), resulting in altered host defense and drug metabolism.

6 ized as a xenobiotic receptor that regulates drug metabolism.

7 dy reveals an unexpected function of RIDD in drug metabolism.

8 rgets showed strong enrichment for lipid and drug metabolism.

9 netic memory and a permanent change of liver drug metabolism.

10 responses in these target genes involved in drug metabolism.

11 netic memory and a permanent change of liver drug metabolism.

12 lls exhibit differences related to lipid and drug metabolism.

13 monal regulation and antibiotic synthesis to drug metabolism.

14 f I3S can lead to AHR activation and altered drug metabolism.

15 with altered cardiovascular disease risk and drug metabolism.

16 P450 3A4, one of the key enzymes involved in drug metabolism.

17 ive antiretroviral therapy agents can affect drug metabolism.

18 ymes and transporters involved in xenobiotic/drug metabolism.

19 pic data sets collected in parallel to study drug metabolism.

20 processes ranging from cellular adhesion to drug metabolism.

21 s a significant P450 protein responsible for drug metabolism.

22 pidly analyze interindividual differences in drug metabolism.

23 R and potentially expands the role of AhR in drug metabolism.

24 The expanded cells displayed typical human drug metabolism.

25 tions, specifically cytochrome P450-mediated drug metabolism.

26 P3A) is an enzyme of paramount importance to drug metabolism.

27 and other tissues for immune modulation and drug metabolism.

28 tion of genes that regulate angiogenesis and drug metabolism.

29 as a trigger for both enzyme expression and drug metabolism.

30 now warranted to identify putative roles in drug metabolism.

31 of hormone response, clinical research, and drug metabolism.

32 e P450 2D6, a major human enzyme involved in drug metabolism.

33 lems in bioanalysis for pharmacokinetics and drug metabolism.

34 ontribute to inter-individual variability in drug metabolism.

35 investigate CYP3A functions, especially for drug metabolism.

36 adigm for unraveling bacterial mechanisms in drug metabolism.

37 etabolizing enzymes with a prominent role in drug metabolism.

38 ifically contribute to diurnal modulation of drug metabolism.

39 B outcome by affecting both host defense and drug metabolism.

40 doses of midazolam, and in case of impaired drug metabolism.

41 d human pregnane X receptor (hPXR) regulates drug metabolism.

42 are the primary enzymes involved in phase I drug metabolism.

43 roduced endogenously during tissue injury or drug metabolism.

44 development of complex diseases, and impact drug metabolism.

45 ding bile acid, cholesterol, fatty acid, and drug metabolism.

46 raphy-mass spectrometry (LC-MS) for studying drug metabolism.

47 etics with gnotobiotics to measure brivudine drug metabolism across tissues in mice that vary in a si

48 administrated methylphenidate increases the drug metabolism activity and the neurotransmitter levels

49 FLD is associated with reduced in vivo CYP3A drug-metabolism activity and hepatic CYP3A4 expression i

50 ediated down-regulation, thereby normalizing drug metabolism after rewarming.

51 is known about the impact of hypothermia on drug metabolism after rewarming.

52 Comparison of EME-MS with LC-MS for drug metabolism analysis demonstrated for the first time

53 The CYP3A4 is involved in drug metabolism and acquisition of drug resistance.

54 Muscle is also important in drug metabolism and adverse events, and the application

55 actions that can lead to altered kinetics in drug metabolism and altered elimination rates in vivo.

56 ormation, such as drug-to-antibody ratio and drug metabolism and are more readily analyzed by electro

57 We discovered that several drug metabolism and BA transporter genes were down-regul

58 cytochrome P450 (CYP) gene family catalyzes drug metabolism and bioactivation and is therefore relev

59 n turnover can influence clinically relevant drug metabolism and bioavailability and drug-drug intera

60 apeutic protocols, and ethnic differences in drug metabolism and bioavailability of the agents common

61 the effects of specific genetic variants on drug metabolism and cancer development.

62 t also in several key areas, particularly in drug metabolism and chemical toxicology, as chemists dea

63 cally relevant inhibitory cross-talk between drug metabolism and cholesterol/glucose metabolism.

64 ne X receptor), a regulator of enterohepatic drug metabolism and clearance, results in an unexpected

65 se, drug-drug interactions, drug dosage, and drug metabolism and clearance.

66 These enzymes dominate drug metabolism and determine drug-drug interactions.

67 coordinated regulation of genes involved in drug metabolism and detoxification as well as maintenanc

68 entrally regulates both phase I and phase II drug metabolism and detoxification.

69 Cytochromes P450 play key roles in drug metabolism and disease by oxidizing a wide variety

70 s of other membrane P450 enzymes involved in drug metabolism and disease states.

71 olateral transporters that are important for drug metabolism and displayed key functional aspects of

72 ted disease screening; crop protection data; drug metabolism and disposition data and bioactivity dat

73 has revised the Instructions to Authors for Drug Metabolism and Disposition, Journal of Pharmacology

74 X receptor (PXR) regulates genes involved in drug metabolism and disposition.

75 in the expression of other genes involved in drug metabolism and disposition.

76 cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.

77 o predict the role of human CYP2C enzymes in drug metabolism and drug-drug interactions is limited.

78 The throughput of this platform may enable drug metabolism and drug-drug interactions to be interro

79 ng with ABC transporters that act to control drug metabolism and efflux.

80 ed drugs and serves as a master regulator of drug metabolism and excretion gene expression in mammals

81 yperforin induces the expression of numerous drug metabolism and excretion genes in primary human hep

82 e shown to induce the expression of numerous drug metabolism and excretion proteins.

83 gulates various liver functions ranging from drug metabolism and excretion to energy metabolism.

84 ulator of the expression of genes central to drug metabolism and excretion.

85 Historically, they have a central role in drug metabolism and following the advent of genomics the

86 a powerful tool for predicting MARC-mediated drug metabolism and further investigating MARC's roles i

87 regulate their target genes, modulating both drug metabolism and gluconeogenesis.

88 chrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug rea

89 xic oxygen metabolites that are generated by drug metabolism and immune responses in addition to thos

90 tereoselective drug metabolite synthesis and drug metabolism and inhibition assays.

91 new bioanalytical platform of HLM useful for drug metabolism and inhibition assays.

92 ed on additional literature data on in vitro drug metabolism and inhibition potency, loratadine and s

93 The effects of drug metabolism and KCNH2 genotypes on clinical response

94 In vitro and in vivo drug metabolism and pharmacokinetic (DMPK) evaluation al

95 ial dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties fo

96 sistent with a high probability of favorable drug metabolism and pharmacokinetic properties, includin

97 gents can be modified to possess appropriate drug metabolism and pharmacokinetic properties.

98 ounds with ample isotopic incorporations for drug metabolism and pharmacokinetic studies.

99 To simulate label-free applications of drug metabolism and pharmacokinetics (DMPK) analysis and

100 s series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, prec

101 that demonstrated an excellent cross-species drug metabolism and pharmacokinetics (DMPK) profile and

102 This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties a

103 is not a P-gp substrate and shows excellent drug metabolism and pharmacokinetics (DMPK) properties w

104 domain inhibitors with excellent potency and drug metabolism and pharmacokinetics (DMPK) properties w

105 r Malaria Venture (MMV) met the efficacy and drug metabolism and pharmacokinetics (DMPK) requirements

106 Sex differences in drug metabolism and pharmacokinetics also occur in human

107 l molecule antagonists with GPR103 affinity, drug metabolism and pharmacokinetics and safety paramete

108 cular chirality remain an important issue in drug metabolism and pharmacokinetics for the pharmaceuti

109 ellular activity, physicochemical as well as drug metabolism and pharmacokinetics properties and fina

110 d selective hEP4-R antagonist with excellent drug metabolism and pharmacokinetics properties.

111 We report in vitro drug metabolism and properties profiling of 4c and show

112 s involved in oncogenic, tumour suppression, drug metabolism and resistance, in patients with metasta

113 g cooling and the effects after rewarming on drug metabolism and response.

114 gy and pharmacokinetics of 1, along with its drug metabolism and safety assessment.

115 r-deficient PIRF mice can thus predict human drug metabolism and should be useful for preclinical dru

116 IdeS digestion, minimizes assay artifacts of drug metabolism and skewed DAR profiles that may result

117 genetic variants selected a priori based on drug metabolism and targets have the greatest potential

118 athogenesis and focused on genes involved in drug metabolism and the immune response.

119 inal (GI) physiology, GI neuroendocrinology, drug metabolism and toxicity, obesity and liver disease.

120 se modeling, host-pathogen interactions, and drug metabolism and toxicity.

121 of liver biology, liver diseases, as well as drug metabolism and toxicity.

122 iocompatibility and relevance for evaluating drug metabolism and toxicity.

123 ystem will be crucial for studies evaluating drug metabolism and toxicology using in vitro constructs

124 es involved in GC signaling (GR, GLCCI1) and drug metabolism and transport (CYP3A5, ABCB1, and PXR) w

125 id-based therapies from the point of view of drug metabolism and transport to target tissues.

126 It covers all drug metabolism and transportation enzymes.

127 f this isoform is important in understanding drug metabolism and xenobiotic detoxification.

128 of infrared ion spectroscopy in the field of drug metabolism and, more generally, its promising role

129 Expertise in HCV antiviral resistance, drug metabolism, and drug-drug interactions and optimiza

130 P450s play an important role in drug metabolism, and have potential uses as biocatalysts

131 relevance to the evolution of new functions, drug metabolism, and in vitro biocatalyst engineering.

132 s the dominant P450 enzyme involved in human drug metabolism, and its inhibition may result in advers

133 ing decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that

134 y acid elongation, cholesterol biosynthesis, drug metabolism, and methemoglobin reduction.

135 ncluding suppression of apoptosis, increased drug metabolism, and modification of target proteins.

136 invaluable for studies of oxidative stress, drug metabolism, and other pathways that involve gamma-g

137 Despite widespread use in pharmacokinetic, drug metabolism, and pesticide residue studies, little i

138 uence GSTP1's contribution to carcinogen and drug metabolism, and possibly disease pathogenesis and/o

139 erial phyla, encoding antibiotic resistance, drug metabolism, and stress response pathways.

140 llosteric pharmacology, medicinal chemistry, drug metabolism, and validated approaches to address eac

141 ndent variations in nitroreductase activity, drug metabolism, and/or actual oxygen gradients.

142 bles, such as drug plasma levels (exposure), drug metabolism, and/or their transport across the blood

143 n in such diverse physiological processes as drug metabolism (approximately 85-90% of therapeutic dru

144 Although the effects of polyI:C on drug metabolism are often attributed to interferon produ

145 P2E1 has in normal physiology, toxicity, and drug metabolism are related to its ability to metabolize

146 Sex-based differences in drug metabolism are the primary cause of sex-dependent p

147 mmals experience an aging-related decline in drug metabolism as well as a diminution in growth hormon

148 In humans this may lead to altered drug metabolism, as many of the newly synthesized ligand

149 n on the similarities and dissimilarities in drug metabolism between the young and old, as may be unc

150 ssed cytosolic enzyme important in exogenous drug metabolism but the physiological function of which

151 a transcription factor that induces hepatic drug metabolism by activating cytochrome P450 genes.

152 or drug abuse treatment is to accelerate the drug metabolism by administration of a drug-metabolizing

153 Ub-ligases can influence clinically relevant drug metabolism by effectively regulating the physiologi

154 topharmacological tools to optically control drug metabolism by modulating the activity of a metaboli

155 atories have demonstrated that activation of drug metabolism by P450s may occur via a mechanism that

156 to enable experiments, for example, to study drug metabolism by use of precision-cut liver slices, th

157 coordinated activation of genes involved in drug metabolism, by blocking activation of a specific su

158 terindividual pharmacokinetic differences in drug metabolism can be identified by computational genet

159 Induction of hepatic and intestinal drug metabolism can contribute to the increased metaboli

160 flammatory responses and infections decrease drug metabolism capacity in human and experimental anima

161 he gut microflora has a direct impact on the drug metabolism capacity of the host.

162 ment, individualized subtherapeutic tests of drug metabolism, carbon dating and real time monitoring

163 further delineate the energy metabolism and drug metabolism crosstalk in this study, we exposed HepG

164 his protocol to a key human P450 involved in drug metabolism: CYP3A4.

165 and longevity, notably pathways involved in drug metabolism/degradation (nicotine and melatonin).

166 Hepatic drug metabolism develops early in organogenesis and cont

167 genes are related to disease phenotypes and drug-metabolism differences in the population.

168 bout the importance of nutritional status on drug metabolism, distribution, and effectiveness.

169 sidering in vivo effects such as quiescence, drug metabolism, drug properties, and transport consider

170 uch variations may involve genes controlling drug metabolism, drug transport, disease susceptibility,

171 including synthesis of human proteins, human drug metabolism, drug-drug interaction, and drug-induced

172 echanisms underlying altered CYP2D6-mediated drug metabolism during pregnancy, laying a foundation fo

173 Conventional methods for assaying drug metabolism (e.g., those based on HPLC) have been es

174 carboxylesterase 1 (hCE1), a broad-spectrum drug metabolism enzyme, in covalent acyl-enzyme intermed

175 l structure of any region of a mammalian UGT drug metabolism enzyme.

176 (UGT) are the dominant phase II conjugative drug metabolism enzymes that also play a central role in

177 cription factor regulating the expression of drug metabolism enzymes, including transporters.

178 (hPXR) regulates the expression of critical drug metabolism enzymes.

179 ted for genes involved in small molecule and drug metabolism, especially butyrylcholinesterase (BCHE)

180 ted metabolic and oxidative phosphorylation, drug metabolism, fatty acid metabolism, and intestinal m

181 any pathological conditions, such as altered drug metabolism, fatty liver, and diabetes.

182 nriched for biological processes relevant to drug metabolism for FBZ and FLU, respectively.

183 nderstanding of PXR, the master regulator of drug metabolism gene expression in humans, in its functi

184 istance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate d

185 ive stress, whereas up-regulation of phase I drug metabolism genes by RXRalpha may render the liver m

186 data suggest that pretreatment evaluation of drug metabolism genes may explain some interindividual d

187 on of hepatic, rather than small intestinal, drug metabolism genes would contribute to the increased

188 hed for lipid homeostasis, hypertension, and drug metabolism genes.

189 Ralpha to control the expression of numerous drug metabolism genes.

190 DNA was genotyped for 29 polymorphisms in 17 drug metabolism genes.

191 ssues, although its relative contribution to drug metabolism has yet to be ascertained.

192 Reactive intermediates produced during drug metabolism have been implicated as a cause of DILI,

193 th substrates of key enzymes responsible for drug metabolism (i.e. cytochrome P450 [CYP] 3A4, CYP1A2)

194 , disease mechanisms, genetic variation, and drug metabolism in a more physiologically relevant setti

195 metabolites is a key issue for the study of drug metabolism in biological systems.

196 Untreated type 1 diabetes increases hepatic drug metabolism in both human patients and rodent models

197 serum shock to study how time of day shifts drug metabolism in cells.

198 from Eggerthella lenta These enzymes predict drug metabolism in complex human gut microbiotas.

199 e in considering interpopulation patterns of drug metabolism in epidemiological and pharmacogenetic s

200 ent in regulating selected genes involved in drug metabolism in fish, but suggest some divergence in

201 ore difficult to treat, due to mechanisms of drug metabolism in hepatic and renal failure, as well as

202 e P450 3A4 (CYP3A4), plays critical roles in drug metabolism in hepatocytes that are either quiescent

203 CYP3A4, the most important P450 catalyst of drug metabolism in human liver.

204 substantially affect intestinal and systemic drug metabolism in mice, and can explain the drug-metabo

205 The CAR-dependent induction of drug metabolism in newly diagnosed or poorly managed typ

206 Viral infections are often linked to altered drug metabolism in patients; however, the underlying mol

207 The functional significance of drug metabolism in skin and the implication of CYP in sk

208 ive intermediates generated in the course of drug metabolism in the human liver is of great importanc

209 ally, organ-on-a-chip models demonstrate how drug metabolism in the liver affects multi-organ toxicit

210 well as the implications of liver injury on drug metabolism in this patient population.

211 iologically relevant culture system to study drug metabolism in vitro, were used to investigate this

212 elopment of inhibitors for use in modulating drug metabolism in vivo.

213 arance, a surrogate marker of CYP3A-mediated drug metabolism, in critically ill children.

214 es and in activation of pathways involved in drug metabolism, including those involved in metabolizin

215 amples including human urine sample and P450 drug metabolism incubation mixture were tested.

216 at in vivo administration of polyI:C affects drug metabolism independent of type I interferon product

217 450 enzymes involved in arachidonic acid and drug metabolism, inflammation and immune responses, mito

218 in mouse and rat liver, affecting lipid and drug metabolism, inflammation, and disease.

219 Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels a

220 and copper), photosynthesis (manganese) and drug metabolism (iron).

221 GIT microbiota participation in drug metabolism is a further pharmaceutical consideratio

222 Individual variation in drug metabolism is a major cause of unpredictable side e

223 t microbiota directly and indirectly affects drug metabolism is beginning to emerge.

224 ever, quantifying microbial contributions to drug metabolism is challenging, particularly in cases wh

225 Drug metabolism is controlled by a class of orphan nucle

226 Mapping the enzymes that contribute to drug metabolism is important since an exaggerated depend

227 During hypothermia, drug metabolism is markedly reduced.

228 mine whether, like other sexual dimorphisms, drug metabolism is permanently imprinted by perinatal ho

229 t area of investigation, the role of PON1 in drug metabolism, is also discussed.

230 CYP) 3A4, the most important enzyme in human drug metabolism, is decreased in uremia.

231 h Quality in Pharmaceutical Development (IQ) Drug Metabolism Leadership Group.

232 the activity of several enzymes involved in drug metabolism, leading to decreased plasma concentrati

233 Examples presented here include drug metabolism, lipid analysis, metabolomics, quantitat

234 hepatocytes that activates genes involved in drug metabolism, lipid homeostasis, and cell proliferati

235 Individual genetic variations in drug metabolism may contribute to increased cardiac even

236 We discuss here the effect of drug metabolism mediated by cytochrome P450 on therapeut

237 the first example of successfully combining drug metabolism, metabolomics, and cell engineering to c

238 Through the extraction of various facts of drug metabolism, not only the DDIs that are explicitly m

239 s Carbohydrate metabolism, Lipid metabolism, Drug metabolism, Nucleotide metabolism.

240 wed that CYP2D6 is significantly involved in drug metabolism of codeine, tamoxifen, and citalopram.

241 o predict pathways of human CYP2D6-dependent drug metabolism on the basis of animal studies.

242 Besides their role in N-reductive drug metabolism, only little is known about their physio

243 TLs without the involvement of intracellular drug metabolism or antigen processing.

244 tations) or upstream of this interaction, in drug metabolism or drug transport mechanisms.

245 be used to identify variants that influence drug metabolism or interaction of a drug with its cellul

246 prior literature, targeting genes related to drug metabolism, oxidative damage, altered neurotransmis

247 or pharmacodynamics of antileukemic agents, drug metabolism, oxidative stress, and attention problem

248 or measuring the activity of a key enzyme of drug metabolism, P450 3A4.

249 onducted using the search terms hypothermia, drug metabolism, P450, critical care, cardiac arrest, tr

250 n mounting evidence of crosstalk between the drug metabolism pathway and the energy metabolism pathwa

251 PXR plays a vital role in the drug metabolism pathway, and a comprehensive examination

252 Identifying individual genetic variation in drug metabolism pathways is of importance not only in li

253 Testing for variation in other drug metabolism pathways may also become important.

254 eukocyte antigen genes and genes involved in drug metabolism pathways.

255 m 60 animals with extreme (i.e. fast or slow drug metabolism) pharmacokinetic (PK) profiles were gene

256 important enzyme, improving the outcomes for drug metabolism predictions, and developing pharmaceutic

257 Photorhabdus transforms tapinarof into novel drug metabolism products that kill inflammatory bacteria

258 vel high-throughput 96-well plate format for drug metabolism profiling.

259 equirement, surgical site infection, delayed drug metabolism, prolonged recovery, shivering, and ther

260 pe, and with appropriate pharmacokinetic and drug metabolism properties, these compounds could be dev

261 d cell proliferation and survival as well as drug metabolism, providing insights into the pathogenesi

262 The impact of the drug metabolism rate on patient survival was also discus

263 The extensive role of CYP3A4 in drug metabolism reflects in part the plasticity of the s

264 e is known about the role of this pathway in drug metabolism regulation in human liver.

265 ces, predictive tools and visualizations for drug metabolism researchers.

266 mate and inextricable role in all aspects of drug metabolism, safety, and effectiveness.

267 ecific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted func

268 important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods

269 Genetic and developmental studies on hepatic drug metabolism show that immaturity, polymorphisms, and

270 ulation pharmacology studies, and indeed for drug metabolism studies in general.

271 hip as a complementary tool for a variety of drug metabolism studies in the early stages of drug disc

272 ransplantation, and cytochrome P450 (CYP450) drug metabolism studies), mitigates risk associated with

273 hat it is important to include MAO assays in drug metabolism studies.

274 measurement for metabolite identification in drug metabolism studies.

275 A drug metabolism study revealed that an imidazole, but no

276 acil and flutamide, and is extendable to any drug metabolism study where there is a spin-active X-nuc

277 ) are the major enzymatic detoxification and drug metabolism system.

278 ide hydrolase (sEH) is an enzyme involved in drug metabolism that catalyzes the hydrolysis of epoxide

279 ndividual cells, as well as variabilities in drug metabolism, the effect of these on phospholipidosis

280 Optimization of properties related to drug metabolism then culminated in the identification of

281 capabilities and can augment CYP3A4-mediated drug metabolism, thereby reducing drug efficacy and pote

282 ses, and the roles for UGT1A1 and SLCO1B1 in drug metabolism, these genetic findings have potential c

283 2C, and CYP2D, which are critical enzymes in drug metabolism, thus affecting the effectiveness of the

284 ish key physiological processes ranging from drug metabolism to steroidogenesis, human microsomal cyt

285 re recognizing differences in tumor biology, drug metabolism, toxicity, and therapeutic response amon

286 ochrome P450s (P450s) play critical roles in drug metabolism, toxicology, and metabolic processes.

287 However, altered drug metabolism, transport, or other related mechanisms

288 nces were observed for GC signaling or other drug metabolism/transport-related genes.

289 CYP2C6 and CYP2C7, both in vitro and in vivo drug metabolism was more rapid in the phenobarbital-impr

290 th IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutrope

291 t of the consequences of differential CYP2D6 drug metabolism, we have developed a novel straightforwa

292 To understand these differences in drug metabolism, we wanted to generate mutations at indi

293 Previous suggestions of autoinduction of drug metabolism were not confirmed by this study.

294 Conversely, genes involved in xenobiotic and drug metabolism were up-regulated, which was linked to i

295 elated to proliferative response, but not to drug metabolism, were differentially expressed in [MET K

296 ly widespread in biology and particularly in drug metabolism, where the need for rapid screening of n

297 yed increased cellular growth, movement, and drug metabolism, whereas the center of the lesion was ch

298 microbiomes to interpersonal differences in drug metabolism, which has implications for medical ther

299 efine gene variations responsible for varied drug metabolism, which influences drug efficacy.

300 atalyze various oxidative transformations in drug metabolism, xenobiotic degradation, and natural pro